Suh Gil Joon, Shin Tae Gun, Kwon Woon Yong, Kim Kyuseok, Jo You Hwan, Choi Sung-Hyuk, Chung Sung Phil, Kim Won Young
Department of Emergency Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Research Center for Disaster Medicine, Seoul National University Medical Research Center, Seoul, Korea.
Clin Exp Emerg Med. 2023 Sep;10(3):255-264. doi: 10.15441/ceem.23.065. Epub 2023 Jul 13.
Although the Surviving Sepsis Campaign guidelines provide standardized and generalized guidance, they are less individualized. This review focuses on recent updates in the hemodynamic management of septic shock. Monitoring and intervention for septic shock should be personalized according to the phase of shock. In the salvage phase, fluid resuscitation and vasopressors should be given to provide life-saving tissue perfusion. During the optimization phase, tissue perfusion should be optimized. In the stabilization and de-escalation phases, minimal fluid infusion and safe fluid removal should be performed, respectively, while preserving organ perfusion. There is controversy surrounding the use of restrictive versus liberal fluid strategies after initial resuscitation. Fluid administration after initial resuscitation should depend upon the patient's fluid responsiveness and requires individualized management. A number of dynamic tests have been proposed to monitor fluid responsiveness, which can help clinicians decide whether to give fluid or not. The optimal timing for the initiation of vasopressor agents is unknown. Recent data suggest that early vasopressor initiation should be considered. Inotropes can be considered in patients with decreased cardiac contractility associated with impaired tissue perfusion despite adequate volume status and arterial blood pressure. Venoarterial extracorporeal membrane oxygenation should be considered for refractory septic shock with severe cardiac systolic dysfunction.
尽管拯救脓毒症运动指南提供了标准化和通用的指导,但它们缺乏个性化。本综述聚焦于脓毒性休克血流动力学管理的最新进展。脓毒性休克的监测和干预应根据休克阶段进行个体化。在挽救阶段,应给予液体复苏和血管升压药以提供挽救生命的组织灌注。在优化阶段,应优化组织灌注。在稳定和降阶梯阶段,应分别进行最小量液体输注和安全的液体清除,同时维持器官灌注。初始复苏后采用限制性与开放性液体策略仍存在争议。初始复苏后的液体管理应取决于患者的液体反应性,需要个体化处理。已提出多种动态试验来监测液体反应性,这有助于临床医生决定是否给予液体。启动血管升压药的最佳时机尚不清楚。近期数据表明应考虑早期启动血管升压药。对于尽管容量状态和动脉血压充足但仍存在与组织灌注受损相关的心脏收缩力下降的患者,可考虑使用正性肌力药物。对于伴有严重心脏收缩功能障碍的难治性脓毒性休克,应考虑采用静脉-动脉体外膜肺氧合。